Shares of Halozyme Therapeutics (NASDAQ:HALO) decreased in after-market trading after the company reported Q4 results.
Earnings per share were up 308.33% over the past year to $0.50, which missed the estimate of $0.53.
Revenue of $121,703,000 rose by 126.78% year over year, which beat the estimate of $120,160,000.
Halozyme Sees FY21 Sales $375M-$395M Vs ...
Full story available on Benzinga.com